Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.69 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.69 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6941567 | 1.00 | GNAO1 (0.69) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL6941550 | 0.98 | GNAO1 (0.66) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL7227872 | 0.98 | GNAO1 (0.66) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL6945447 | 0.93 | GNAO1 (0.74) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL8108378 | 0.93 | GNAO1 (0.74) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL6939850 | 0.93 | GNAO1 (0.74) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL6943025 | 0.93 | GNAI3 (0.62) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL6944539 | 0.91 | GNAO1 (0.71) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL8115260 | 0.91 | GNAO1 (0.71) | GNAO1GNAI3GNAI1SPHK1HRH3 | |
| SCHEMBL6948316 | 0.88 | GNAI3 (0.66) | GNAO1GNAI3GNAI1SPHK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | GNAO1 2886/4885GNAI3 2099/4885GNAI1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.